Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers

Current Medical Research and Opinion

Volumn 21, Issue 4, 2005, Pages 595-601

  Shah, Ajit K ^a   Hunt, Thomas L ^b   Gallagher, Susan C ^a   Cullen Jr , Michael T ^a  

^a GUILFORD PHARMACEUTICALS INC   (United States)

^b Pharmaceutical Product Development   (United States)

Author keywords

Aprepitant; Drug interaction; Nausea and vomiting; Palonosetron; Pharmacokinetics

Indexed keywords

APREPITANT; PALONOSETRON; SEROTONIN 3 ANTAGONIST; SUBSTANCE P ANTAGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIEMETICS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; MALE; MORPHOLINES; QUINUCLIDINES;

EID: 18744383973     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X40481     Document Type: Article

References (23)

1. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17:2971-4
2. Perez EA. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis. Drug Safety 1998;18:43-56
3. Cohen L, DeMoor C, Eisenberg P, et al. Delayed chemotherapy-induced nausea and vomiting (CINV) remains a problem and significantly interferes with daily function (DF) in patients receiving emetogenic chemotherapy (CT) in the United States. Proc Am Soc Clin Oncol 2003;22:739 [Abstract 2972]
4. Grunberg SM, Deuson R, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-8
5. Aloxi® [package insert]. Lugano, Switzerland: Helsinn Healthcare SA; 2003
6. Zofran® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2004
7. Kytril® [package insert]. Nutley, NJ: Roche Laboratories; 2002
8. Anzemet® [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals; 2003
9. Wong EH, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. B J Pharmacol 1995;114:851-9
10. Miller RC, Galvan M, Gittos MW, Vangiersbergen PLM, Moser PC, Fozard JR. Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 1993;28:87-93
11. Aapro M, Bertoli L, Lordick F, et al. Palonosetron (PALO) is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Supp Care Cancer 2003;11:391 [Abstract A-17]
12. 3 receptor antagonist. Cancer 2003;98:2473-82
13. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7
14. Stoltz R, Cyong J-C, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J Clin Pharmacol 2004;44:520-31
15. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based, chemotherapy: a dose-ranging, clinical study. Ann Oncol 2004;15:330-37
16. Stoltz R, Parisi S, Shah A, Macciocchi A. Pharmacokinetics, metabolism, and excretion of intravenous [14C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos 2004;25:329-37
17. Emend® [package insert]. Whitehouse Station, NJ: Merck & Co; 2003
18. Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:1407-19
19. US Department of Health and Human Services. Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analyses, and Recommendations for Dosing and Labeling. Washington, DC: US Department of Health and Human Services, 1999
20. 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17-24
21. 3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J 2002;8:405-14
22. McCrea J, Majumdar A, Busillo J, et al. Lack of effect of aprepitant on the pharmacokinetics of ondansetron. Clin Pharmacol Ther 2003;73:PI-18
23. Petty KJ, Majumdar A, Orlowski LH, et al. Lack of effect of aprepitant on the pharmacokinetics of granisetron. Clin Pharmacol Ther 2003;73:PI-19